Guardant Health, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B.
During the fiscal quarter ended December 31, 2025, none of our directors or officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, except as described in the table below:
| Name and Title of Insider | Adoption, Modification or Termination | Applicable Date | Duration of Trading Arrangement | Rule 10b5-1 Trading Arrangement?(Y / N) (1) | Aggregate Number of Securities Subject to the Trading Arrangement |
|---|---|---|---|---|---|
| AmirAli Talasaz, Co-Chief Executive Officer and Director | Adoption | 12/5/2025 | 3/4/2026-6/30/2027 | Y | 520,000 |
| John Saia, Chief Legal Officer and Secretary | Adoption | 12/16/2025 | 3/18/2026 - 3/17/2027 | Y | 30,000 |
| Musa Tariq, Director | Adoption | 12/17/2025 | 3/18/2026 - 3/16/2027 | Y | Indeterminable(2) |
(1)Denotes whether the trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) when adopted.
(2)Mr. Tariq’s 10b5-1 trading plan provides for the sale of 46.4% of an indeterminable number of shares of our common stock underlying certain restricted stock unit awards that will vest during the duration of the trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.